Currently out of the existing stock ratings of Konstantinos Aprilakis, 12 are a BUY (75%), 3 are a HOLD (18.75%), 1 are a SELL (6.25%).

Konstantinos Aprilakis

Work Performance Price Targets & Ratings Chart

Analyst Konstantinos Aprilakis, currently employed carries an average stock price target met ratio of 65% that have a potential upside of 38.66% achieved within 303 days. Previously, Konstantinos Aprilakis worked at STIFEL, DEUTSCHE BANK.

Konstantinos Aprilakis’s has documented 32 price targets and ratings displayed on 6 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on DCPH, Deciphera Pharmaceuticals LLC at 03-Dec-2020.

Wall Street Analyst Konstantinos Aprilakis

Analyst best performing recommendations are on STRO (SUTRO BIOPHARMA).
The best stock recommendation documented was for STRO (SUTRO BIOPHARMA) at 12/3/2020. The price target of $25 was fulfilled within 36 days with a profit of $8 (47.06%) receiving and performance score of 13.07.

Average potential price target upside

of $11.49 (61.26%) on KURA (KURA ONCOLOGY).
of $10.44 (12.15%) on BPMC (BLUEPRINT MEDICINES CORP).
of $9.42 (72.01%) on STRO (SUTRO BIOPHARMA).

BPMC Blueprint Medicines Corp DCPH Deciphera Pharmaceuticals LLC KURA Kura Oncology SNDX Syndax Pharmaceuticals STRO Sutro Biopharma MOR MorphoSys AG ADR

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Ami Fadia (NEEDHAM)